Popular Trials
Anti-metabolites
Azacitidine + Chemotherapy for Acute Lymphoblastic Leukemia
This trial is testing azacitidine in combination with chemotherapy to see if it is more effective in treating infants with acute lymphoblastic leukemia who have KMT2A gene rearrangement.
Popular Filters
Trials for T-Cell Lymphoblastic Leukemia Patients
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer treatment involving genetically modified cells from the patient's own body. The goal is to find the maximum tolerated dose and to determine efficacy.
Alkylating agents
IMRT + Chemotherapy + Stem Cell Transplant for Leukemia
This trial is giving IMRT with chemotherapy to patients with relapsed or refractory ALL or AML before a donor stem cell transplant. The aim is to find out the side effects of this treatment and the best dose of IMRT to give, as well as how well the IMRT and chemotherapy work in treating patients.
Trials for ALL Patients
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer treatment involving genetically modified cells from the patient's own body. The goal is to find the maximum tolerated dose and to determine efficacy.
Trials for CD19 Positive Patients
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer treatment involving genetically modified cells from the patient's own body. The goal is to find the maximum tolerated dose and to determine efficacy.
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is for patients with relapsed or refractory CD19+ acute lymphoblastic leukemia (ALL) who are between the ages of 0 and 30. The trial will test the safety and effectiveness of a new treatment called chimeric antigen receptor (CAR) T cell therapy. In this therapy, patient's own immune cells are collected and then manufactured to be more effective at killing cancer cells. The product will be made at the St. Jude Children's Research Hospital's Good Manufacturing Practice (GMP) facility. The trial will test different doses of the therapy to find the largest safe dose, as well as how long the therapy lasts in the
Trials for Philadelphia Chromosome Positive Patients
Monoclonal Antibodies
Immunotherapy + Chemotherapy for Acute Lymphoblastic Leukemia
This trial tests a new treatment combining inotuzumab ozogamicin and chemotherapy for elderly patients with acute lymphoblastic leukemia. The drug targets and kills cancer cells, aiming to improve outcomes for those who can't undergo intensive therapy or have had a recurrence. The study will determine the appropriate dose and evaluate the treatment's effectiveness and side effects.
Monoclonal Antibodies
Blinatumomab + Chemotherapy/Dasatinib for Acute Lymphoblastic Leukemia
This trial is studying the side effects and efficacy of blinatumomab and combination chemotherapy or dasatinib and prednisone in treating older patients with acute lymphoblastic leukemia.
Phase 3 Trials
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
Trials With No Placebo
Corticosteroid
Chemotherapy Regimen for Acute Lymphoblastic Leukemia
This trial is studying a new way to treat acute lymphoblastic leukemia (ALL). The new way involves using a new, updated set of risk factors to decide how strong the treatment will be and testing a new way of dosing a chemotherapy drug.
CAR T-cell Therapy
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
This trial is testing a new cancer treatment involving genetically modified cells from the patient's own body. The goal is to find the maximum tolerated dose and to determine efficacy.
Alkylating agents
IMRT + Chemotherapy + Stem Cell Transplant for Leukemia
This trial is giving IMRT with chemotherapy to patients with relapsed or refractory ALL or AML before a donor stem cell transplant. The aim is to find out the side effects of this treatment and the best dose of IMRT to give, as well as how well the IMRT and chemotherapy work in treating patients.
View More Related Trials
Frequently Asked Questions
Introduction to all
What are the top hospitals conducting all research?
In the world of medical research, hospitals play a crucial role in conducting clinical trials to find new treatments and cures for various conditions. When it comes to all types of clinical trials, some esteemed institutions stand out from the rest. One such hospital is the M D Anderson Cancer Center in Houston, which leads the way with an impressive 16 active trials encompassing different diseases and conditions. Interestingly, this renowned center has yet to conduct any previous all-time trials, highlighting their commitment to cutting-edge research that constantly seeks innovative solutions.
Meanwhile, on the west coast in Los Angeles, Children's Hospital Los Angeles is making significant strides with 15 ongoing all-type clinical trials. Similarly driven by a passion for advancing medicine and pediatric care, they have yet to complete any prior all-time trials but are actively contributing towards novel breakthroughs.
In Orange County lies another dedicated institution: Children's Hospital of Orange County. With 14 active all-type clinical trials underway there as well — covering diverse areas of healthcare — researchers at this facility are fervently working towards improving health outcomes for children and adolescents.
Further north along California's Silicon Valley sits Lucile Packard Children's Hospital at Stanford University in Palo Alto. Here too researchers are vigorously engaged in advancing medical knowledge through conducting 13 ongoing all-type clinical studies. While no previous record exists for completed overall trials at this prestigious teaching hospital affiliated with Stanford University School of Medicine; it continues its relentless pursuit of better understanding numerous ailments afflicting young patients today.
Similarly committed to enhancing pediatric healthcare is Washington D.C.'s Children's National Medical Center where they currently have 13 active all-type clinical studies taking place within their walls – exemplifying unwavering dedication towards advancing child-specific treatment options despite having no previously recorded overall trial history themselves.
These leading hospitals represent beacons of hope amidst countless challenges faced within modern medicine’s vast landscape.They demonstrate how collaboration between talented medical professionals coupled with state-of-the-art facilities can accelerate scientific progress to ultimately ensure better health outcomes for patients of all ages. The ongoing clinical trials at these esteemed institutions offer not only a glimpse into the future but also tangible evidence that groundbreaking discoveries are just around the corner.
Which are the best cities for all clinical trials?
Three cities emerge as leading hubs for a diverse range of clinical trials. Chicago, Illinois tops the list with 52 active trials investigating treatments like Blinatumomab, Pharmacological Study, and Cyclophosphamide. Las Vegas, Nevada closely follows with 51 ongoing studies focusing on AKR1C3-activated Prodrug OBI-3424, Pharmacological Study, and Arm A (imatinib mesylate, EsPhALL chemotherapy). New york City boasts 44 active trials exploring treatments such as Arm A (imatinib mesylate, EsPhALL chemotherapy), Pharmacological Study, and brexucabtagene autoleucel. These cities serve as thriving centers for cutting-edge research that holds promise for advancing medical knowledge and improving patient outcomes.
Which are the top treatments for all being explored in clinical trials?
In the realm of clinical trials, several top treatments are currently being explored to treat breast cancer. These include:
- Daratumumab: 6 active trials, 134 all-time breast cancer trials (first listed in 2012)
- Belantamab mafodotin: 4 active trials, 26 all-time breast cancer trials (first listed in 2018)
- Lenalidomide: 3 active trials for breast cancer, and a remarkable total of 280 all-time clinical trials (first listed in 2003)
The continuous research and development of these treatments provide hope for advancements in combating this devastating disease.
What are the most recent clinical trials for all?
In the realm of clinical trials for acute lymphoblastic leukemia (ALL), several recent studies offer hope and potential advancements in treatment options. One such trial investigates the efficacy of blinatumomab, a promising therapy being tested in Phase 2 trials. Additionally, fludarabine, cyclophosphamide, and alemtuzumab have shown promise as a combined regimen for ALL patients in both Phase 1 and Phase 2 trials. Another study focuses on the use of hyper-CVAD plus calaspargase pegol treatment to combat this aggressive form of cancer. Furthermore, CD19-CAR T cell therapy is under investigation as a potential breakthrough approach to target ALL cells specifically. Lastly, rituximab has demonstrated positive outcomes in Phase 2 trials for individuals with ALL. These ongoing investigations bring renewed optimism to patients battling this challenging disease by exploring innovative solutions that may lead to improved care and better outcomes.
What all clinical trials were recently completed?
Several recent clinical trials have successfully concluded, bringing significant advancements in medical research. Notably, the Washington University School of Medicine completed a trial investigating Uproleselan for multiple myeloma treatment in October 2021. Additionally, the National Cancer Institute concluded their study on mRNA-1273 in September 2021. Finally, AgenTus Therapeutics wrapped up their agenT-797 trial in January 2021. These trials showcase the ongoing dedication of researchers and offer hope for improved treatments across various medical fields.